Hepatitis C Market 2018 Trend, Size and Growth Analysis Report

1
Global Hepatitis C Market 2014-2018
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.

• Published September 2014
• Single User PDF US 3000
• Corporate User PDF US 4000

2
Global Hepatitis C Market 2014-2018

• Hepatitis C is a liver disease caused by
  infection due to hepatitis C virus. Hepatitis C
  infection predominantly affects the liver
  however, other parts of the body are also
  affected such as the brain and the digestive
  system. Hepatitis C virus is an RNA virus
  belonging to the family Flaviviridae and genus
  hepacivirus. It has a positive-sense,
  single-stranded RNA molecule enveloped by a lipid
  bilayer. Hepatitis C can lead to acute infection
  or chronic infection. Nearly 80 percent of the
  infected individuals suffering from acute
  infection are asymptomatic. Symptoms manifested
  in the rest include nausea, dark urine, fever,
  anorexia, gray-colored faces, abdominal pain, and
  joint pain. Nearly 20 percent of infected
  individuals develop jaundice, which is
  characterized by  the yellowing of skin and eyes.
  Nearly 15-45 percent of acutely infected
  individuals recover from the infection
  spontaneously within the first six months of
  infection. This happens because  the immune
  system mediated the clearance of the virus from
  the body. The remaining 55-85 percent of infected
  individuals who fail to clear the virus within
  six months develop chronic hepatitis C phase.
  Chronic infection can lead to mild-to-moderate
  symptoms or chronic symptoms such as liver
  fibrosis, liver cirrhosis, and hepatic cancer.
  The World Health Organization (WHO) estimates
  that globally, 130-150 million people suffer from
  chronic hepatitis B. It also reported that every
  year 350,000-500,000 infected individuals die
  because of hepatitis C-related hepatic disorders.
  Currently, there is no vaccine for the prevention
  of hepatitis C infection however, various
  treatment options for hepatitis C infection are
  available.
• Single User License Available US 3000 Order a
  copy of this report at _at_ http//www.reportsnreport
  s.com/Purchase.aspx?name297407.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
3
Global Hepatitis C Market 2014-2018

• One of the emerging trends in the market is the
  emergence of Interferon -free regimens. Various
  IFN-free regimens are under development as
  all-oral regimens. These therapies are expected
  to attain higher SVR and cause fewer side effects
  than currently approved therapies.
• Analysts forecast the Global Hepatitis C market
  to grow at a CAGR of 19.20 percent over the
  period 2013-2018. According to the report, the
  launch of direct-acting antivirals is one of the
  major drivers of the market. These are
  administered in combination with other antiviral
  drugs such as ribavirin and PEG-IFN. They
  increase the efficacy of treatment and reduce the
  duration of therapy.
• Global Hepatitis C Market 2014-2018, has been
  prepared based on an in-depth market analysis
  with inputs from industry experts. The report
  covers the Americas, and the APAC and EMEA
  regions it also covers the Global Hepatitis C
  market landscape and its growth prospects in the
  coming years. The report includes a discussion of
  the key vendors operating in this market.
• Further, the report states that the side effects
  of current therapies are one of the major
  challenges in the market. Currently, approved
  drugs for hepatitis C are associated with poor
  tolerability and lower patient compliance rates.
  This, in turn, decreases the market revenue of
  the currently approved drugs.
• Inquiry Before Buying on this Report _at_
  http//www.reportsnreports.com/contacts/InquiryBef
  oreBuy.aspx?name297407.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
4
Global Hepatitis C Market 2014-2018

• Covered in this Report
• This report covers the present scenario and the
  growth prospects of the Global Hepatitis C market
  for the period 2014-2018. To calculate the market
  size, the report considers the revenue generated
  through sales of various drugs administered to
  treat chronic hepatitis caused by genotype 1-6 of
  hepatitis C virus.
• Key Regions
• Americas, EMEA APAC
• Key Vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• Johnson Johnson
• Merck Vertex Pharmaceuticals
• Other Prominent Vendors
• Abbvie
• Achillion Pharmaceuticals
• Bristol-Myers Squibb
• Mitsubishi Tanabe Pharma Novartis

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5
Global Hepatitis C Market 2014-2018

• Market Driver
• Increase in Injection Drug Users
• Market Challenge
• Side-effects of Current Therapy
• Market Trend
• Emergence of Interferon-free Therapies
• Key Questions Answered in this Report
• What will the market size be in 2018 and what
  will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats
  faced by the key vendors?
• What are the strengths and weaknesses of the key
  vendors?
• Inquire for Discount _at_ http//www.reportsnreports.
  com/contacts/Discount.aspx?name297407.
• Browse more report on Pharmaceuticals Market

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.